CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study-Reference-Cited by-同舟云学术

CYP2C19 & UGT1A6 genetic polymorphisms and the impact on Valproic acid-induced weight gain in people with epilepsy: Prospective genetic association study

Published:2021-11 Issue: Volume:177 Page:106786
ISSN:0920-1211
Container-title:Epilepsy Research
language:en
Short-container-title:Epilepsy Research

Author:

Mani Balachandran^ORCID,Nair Pradeep Pankajakshan^ORCID,Sekhar Anamika,Kamalanathan Sadishkumar,Narayan Sunil K.^ORCID,Kesavan Ramasamy

Funder

Jawaharlal Institute Of Postgraduate Medical Education and Research

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology

Reference39 articles.

1. Insulin resistance in patients on valproic acid: relation to adiponectin;Aly;Acta Neurol. Scand.,2015

2. Reliability and validity of a new physical activity questionnaire for India;Anjana;Int. J. Behav. Nutr. Phys. Act.,2015

3. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10;Argikar;Drug Metab. Dispos.,2009

4. Metabolic and endocrine effects of valproic acid chronic treatment;Belcastro;Epilepsy Res.,2013

5. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial;Biton;J. Child Neurol.,2003

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of CYP2C19 Genetic Variant and Its Lack of Association with Valproic Acid Plasma Concentrations Among Zhuang and Han Schizophrenia Patients in Guangxi;Pharmacogenomics and Personalized Medicine;2024-05

2. Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review);Safety and Risk of Pharmacotherapy;2024-04-17

3. Impact of ABCB1 genetic polymorphism on carbamazepine dose requirement among Southern Indian persons with epilepsy;Drug Metabolism and Personalized Therapy;2024-03-01

4. Impact of CYP2C9*2 and *3 polymorphisms on valproate-associated adverse drug reactions in individuals living with epilepsy: a case–control study;Personalized Medicine;2023-09

5. Effects of UGT1A, CYP2C9/19 and ABAT polymorphisms on plasma concentration of valproic acid in Chinese epilepsy patients;Pharmacogenomics;2023-02